Registration and prospectus / Jupiter Neurosciences, Inc. | Tables in SEC filings

JUNS Jupiter Neurosciences, Inc.

IPO registration (amended)

Name	Date	Type	Type of Award		Quantity		Price		Additional
Mark Dant, an advisor	April 21, 2020	Granted	Non-qualified Stock Option; Common Stock			90,000	$	0.80
Robert Roath	May 19, 2020	Issued	Common Stock			126,251	$	0.80	Upon his conversion of a promissory note
Joel Norman Goldberg Trust #1, Dated 04/15/2003	June 23, 2020	Issued	Common Stock			156,251	$	0.80
Joel Norman Goldberg Trust #1, Dated 04/15/2003	June 23, 2020	Granted	Warrant; Common Stock			234,375	$	0.80
Andrew C. Matthiesen Trust, Dated 12/03/1998	June 23, 2020	Issued	Common Stock			156,251	$	0.80
Andrew C. Matthiesen Trust, Dated 12/03/1998	June 23, 2020	Granted	Warrant; Common Stock			234,375	$	0.80
Joel Norman Goldberg Trust #1, Dated 04/15/2003	June 23, 2020	Issued	Common Stock			78,123	$	0.80	For services rendered by Joel Norman Goldberg to the Company
Andrew C. Matthiesen Trust, Dated 12/03/1998	June 23, 2020	Issued	Common Stock			78,123	$	0.80	For services rendered by Andrew C. Matthiesen to the Company
Dencam Living Trust	June 29, 2020	Issued	Common Stock			156,251	$	0.80
Dencam Living Trust	June 29, 2020	Granted	Warrant; Common Stock			234,375	$	0.80
Dencam Living Trust	June 29, 2020	Issued	Common Stock			78,123	$	0.80	For services rendered by Robert Faerber to the Company
WKJP, LLC	July 15, 2020	Issued	Common Stock			156,251	$	0.80
WKJP, LLC	July 15, 2020	Granted	Warrant; Common Stock			234,375	$	0.80
WKJP, LLC	July 15, 2020	Issued	Common Stock			78,123	$	0.80	For services rendered by Jeffery W. Krol to the Company
Joel Norman Goldberg Trust #1, Dated 04/15/2003	August 20, 2020	Issued	Common Stock			669,645	$	0.15
Dencam Living Trust	August 20, 2020	Issued	Common Stock			167,411	$	0.15
WKJP, LLC	August 20, 2020	Issued	Common Stock			502,233	$	0.15
Arthur Kirsch, a consultant	October 01, 2020	Granted	Non-qualified Stock Option; Common Stock			150,000	$	1.33
Gene Spotlight, Inc.	December 29, 2020	Issued	Common Stock			375,000	$	1.33
Gene Spotlight, Inc.	December 29, 2020	Granted	Warrant; Common Stock			75,000	$	1.33
Robert S. Roath Revocable Trust	February 19, 2021	Issued	Common Stock			11,373	$	1.33	Upon his conversion of a promissory note
Dana Eschenburg Perez, our former Chief Financial Officer	March 01, 2021	Granted	Incentive Stock Option; Common Stock			135,000	$	1.33
Robert S. Roath	March 05, 2021	Issued	Common Stock			84,375	$	0.80	Upon an exercise of a non-qualified stock option
Alexander Rosén, our Chief Administrative Officer	June 01, 2021	Granted	Incentive Stock Option; Common Stock			168,750	$	2.16
Dana Eschenburg Perez, our former Chief Financial Officer	June 01, 2021	Granted	Incentive Stock Option; Common Stock			193,125	$	2.16
Tiberend Strategic Advisors, a consultant	June 15, 2021	Granted	Non-qualified Stock Option; Common Stock			56,250	$	2.16
W. Dalton Deitrich III, an advisor	June 22, 2021	Granted	Non-qualified Stock Option; Common Stock			67,500	$	2.16
Dencam Living Trust	August 30, 2021	Issued	Common Stock			234,375	$	0.80	Upon the exercise of a warrant
Alison Silva, our President and Chief Business Officer	September 01, 2021	Granted	Incentive Stock Option; Common Stock			281,250	$	2.16
Gene Spotlight, Inc.	September 09, 2021	Issued	Common Stock			75,000	$	1.33	Upon the exercise of a warrant
Joel Norman Goldberg Trust #1, Dated 04/15/2003	September 28, 2021	Issued	Common Stock			234,375	$	0.80	Upon the exercise of a warrant
WKJP, LLC	September 29, 2021	Issued	Common Stock			234,375	$	0.80	Upon the exercise of a warrant
Andrew C. Matthiesen Trust, Dated 12/03/1998	September 30, 2021	Issued	Common Stock			234,375	$	0.80	Upon the exercise of a warrant
Nicholas Hemmerly, a member of our Board of Directors	October 01, 2021	Granted	Non-qualified Stock Option; Common Stock			67,500	$	2.16
Allison W. Brady, a member of our Board of Directors	October 01, 2021	Granted	Non-qualified Stock Option; Common Stock			67,500	$	2.16
Julie Kampf, a member of our Board of Directors	October 01, 2021	Granted	Non-qualified Stock Option; Common Stock			67,500	$	2.16
John Ditton, an advisor	October 01, 2021	Granted	Non-qualified Stock Option; Common Stock			67,500	$	2.16	Such stock options were forfeited on January 15, 2022 (90 days following his resignation as a director of the Company)
Holger Weis, a member of our Board of Directors	October 01, 2021	Granted	Non-qualified Stock Option; Common Stock			67,500	$	2.16
Arthur Kirsch, a consultant	October 01, 2021	Granted	Non-qualified Stock Option; Common Stock	12,500		46,875	$	2.16
Frank Behnam, CEO of Aquanova AG	December 01, 2021	Cancelled	Non-qualified Stock Option; Common Stock			84,375	$	0.80	Issued on October 2018
Aquanova AG	December 01, 2021	Granted	Non-qualified Stock Option; Common Stock			84,375	$	2.16	Pursuant to the terms of the Debt Forgiveness and Exchange Agreement. subject to vesting terms set forth in the non-qualified stock option
An accredited investor	April 11, 2022	Issued	Common Stock			514,403	$	2.16	In connection with the issuance of a senior secured convertible note with a principal amount of $1,111,111 to an accredited investor; as additional consideration to the investor for lending $1,000,000 to the Company
June 1, 2021 Option Grant to Alexander Rosén, our Chief Administrative Officer	July 14, 2022	Amendment	Incentive Stock Option; Common Stock			168,750	$	1.33
June 1, 2021 Option Grant to Dana Eschenburg Perez, our former Chief Financial Officer	July 14, 2022	Amendment	Incentive Stock Option; Common Stock			193,125	$	1.33
August 1, 2021 Option Grant to Dana Eschenburg Perez, our former Chief Financial Officer	July 14, 2022	Amendment	Incentive Stock Option; Common Stock			193,125	$	1.33
June 22, 2021 Option Grant to W. Dalton Dietrich III, an advisor	July 14, 2022	Amendment	Non-qualified Stock Option; Common Stock			67,500	$	1.33
September 1, 2021 Option Grant to Alison D. Silva, our President and Chief Business Officer	July 14, 2022	Amendment	Incentive Stock Option; Common Stock			281,250	$	1.33

Type	Amount
SEC Registration Fee	$	4,686
FINRA Filing Fee		5,263
Nasdaq Capital Market Listing Fee		50,000
Legal Fees and Expenses		200,000
Accounting Fees and Expenses		120,000
Accountable Fees		175,000
Non-Accountable Fees		110,000
Transfer Agent and Registrar’s Fees and Expenses		10,000
Printing and Engraving Expenses		10,000
Miscellaneous Expense		30,051
Total Expenses	$	715,000

Table search / Registration and prospectus / Jupiter Neurosciences, Inc.

221 results

Top filers

Top filing types

Recent filing years